MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells

  • Authors:
    • Qingliang Meng
    • Xiaoqi He
    • Guangwei Xie
    • Qingzhong Tian
    • Xiaogang Shu
    • Jin Li
    • Yong Xiao
  • View Affiliations

  • Published online on: June 30, 2017     https://doi.org/10.3892/ol.2017.6494
  • Pages: 3089-3095
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the association between the mitogen‑activated protein kinase (MAPK) signal transduction pathway and multidrug resistance in hepatocellular carcinoma cells. A Cell Counting Kit‑8 assay was used to determine the drug sensitivity of HepG2 and HepG2/ADM hepatocellular carcinoma cell lines in combination with the MAPK/extracellular‑signal‑regulated kinase kinase (MEK) inhibitor U0126. Flow cytometry was used to analyze the rate of apoptosis. The reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to determine P‑glycoprotein (P‑gp) and multidrug resistance‑associated protein 1 (MRP1) mRNA expression following treatment with various concentrations of U0126. P‑gp and MRP1 expression levels were measured using Western blot analysis. The half‑maximal inhibitory concentration was markedly decreased in combination with U0126. RT‑qPCR results demonstrated that the expression of multidrug resistance 1 (MDR1) and MRP1 in HepG2/ADM cells was increased 5.37‑ and 6‑14‑fold compared with that in HepG2 cells. Furthermore, the expression levels in HepG2/ADM cells were decreased following U0126 treatment in a dose‑dependent manner. The expression of P‑gp and MRP1 in HepG2/ADM cells was increased 2.68‑ and 2.76‑fold compared with that in HepG2 cells. Furthermore, the expression levels in HepG/ADM cells were decreased following U0126 treatment in a dose‑dependent manner. The results of the present study indicate that the MEK inhibitor U0126 enhances sensitivity to chemotherapeutic drugs by downregulating P‑gp and MRP1 expression in resistant hepatocellular carcinoma cells. The combination of MEK inhibitor and conventional chemotherapeutic drugs may provide novel therapeutic prospects for the treatment of drug‑resistant hepatocellular carcinoma.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Meng Q, He X, Xie G, Tian Q, Shu X, Li J and Xiao Y: MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells. Oncol Lett 14: 3089-3095, 2017.
APA
Meng, Q., He, X., Xie, G., Tian, Q., Shu, X., Li, J., & Xiao, Y. (2017). MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells. Oncology Letters, 14, 3089-3095. https://doi.org/10.3892/ol.2017.6494
MLA
Meng, Q., He, X., Xie, G., Tian, Q., Shu, X., Li, J., Xiao, Y."MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells". Oncology Letters 14.3 (2017): 3089-3095.
Chicago
Meng, Q., He, X., Xie, G., Tian, Q., Shu, X., Li, J., Xiao, Y."MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells". Oncology Letters 14, no. 3 (2017): 3089-3095. https://doi.org/10.3892/ol.2017.6494